Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-08-29
2010-11-16
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388800, C530S388850, C530S391700, C424S133100, C424S141100, C424S155100, C424S156100, C435S069600, C435S070210
Reexamination Certificate
active
07834155
ABSTRACT:
Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.
REFERENCES:
patent: 5416064 (1995-05-01), Chari et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5639641 (1997-06-01), Pedersen et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 6333410 (2001-12-01), Chari et al.
patent: 6340701 (2002-01-01), Chari et al.
patent: 6596503 (2003-07-01), Wennerberg et al.
patent: 7507410 (2009-03-01), Kellogg et al.
patent: 2003/0215895 (2003-11-01), Wennerberg et al.
patent: 2004/0241174 (2004-12-01), Godfrey et al.
patent: 4-502408 (1992-05-01), None
patent: 9007861 (1990-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 02/16401 (2002-02-01), None
patent: WO 03/050260 (2003-03-01), None
Fundamental Immunology, William E. Paul, ed., 3rd Ed., pp. 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.
Colman P. M. Research in Immunology, 145:33-36, 1994.
Bendig M. M. Methods: A Companion to Methods in Enzymology, 8:83-93, 1995.
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Raag et al. FASEB J., 9(1):73-80, 1995.
Smith et al,International J. of Gynecological Pathology, 20:260-266 (2001).
Smith et al,Applied Immunohistochemistry&Molecular Morphology, 10(2):152-158 (2002).
Kearse et al,Int. J. Cancer, 88:866-872 (2000).
Smith et al,Human Antibodies, 9:61-65 (1999).
Chun et al, “Potent Anti-Cancer Activity of DS6-DM1, an Antibody-drug Conjugate Targeting aMuc1 Glycotope on Ovarian, Breast, and Pancreatic Carcinomas”, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications Hynes Cancer, Boston, MA, B205 (Nov. 17-21, 2003).
Studnicka et al,Protein Engineering, 7(6):805-814 (1994).
Roguska et al,Protein Engineering, 9(10):895-904 (1996).
Smith et al.; “Patterns of Expression of the DS6-glycoform of MUC1 Correlates with Known Prognostic Indicators in Breast Cancer;” Proceedings of the Annual Meeting of the American Associattion for Cancer Research; New York; vol. 45, Jan. 1, 2004; p. 239, Abstract 1051, XP001247901.
Chun Philip
Payne Gillian
Tavares Daniel J.
Blanchard David J.
Immunogen Inc.
Sughrue & Mion, PLLC
LandOfFree
CA6 antigen-specific cytotoxic conjugate and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CA6 antigen-specific cytotoxic conjugate and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CA6 antigen-specific cytotoxic conjugate and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190167